We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA and EMA approved skipping Phase 3 for Herceptin biosimilar AP063. Learn how this decision will change the biosimilar market and accelerate access to cancer therapy.